Work

Abstract S5-4: EGFR expression measured by quantitative immunofluorescense is associated with decreased benefit from trastuzumab in the adjuvant setting in the NCCTG (Alliance) N9831 trial.

Year: 2012

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/0008-5472.sabcs12-s5-4

Authors: D Rimm, KV Ballman, H Cheng, M Vassilakopoulou, B Chen, J Gralow, C Hudis, NE Davidson, A Psyrri, G Fountzilas, EA Perez

Institutions: Mayo Clinic, Seattle Cancer Care Alliance, Memorial Sloan Kettering Cancer Center, Aristotle University of Thessaloniki, Yale University, UPMC Hillman Cancer Center, University General Hospital Attikon, Mayo Clinic in Florida

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2056727404

Cites:

Cited by: 8

Related to: 10